FDA Approval Insights: Liso-Cel in Refractory Large B-Cell Lymphoma

May 03, 08:12 PM

Dr. Abramson discusses the significance of the FDA approval of liso-cel in refractory large B-cell lymphoma and provided insight into the efficacy and safety profiles of the CAR T-cell therapy as reported in the TRANSCEND NHL 001 trial.